The application from Lykos — a drug enterprise incubated via the Multidisciplinary Affiliation for Psychedelic Scientific tests, or MAPS — arrived for the FDA below a cloud of controversy. Former trial contributors experienced alleged adverse situations weren't noted — which includes inner thoughts of suicidality after the remedy — Which bi… Read More